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CHAPTER I 
 
 
INTRODUCTION 
 
The main objective of this work is to develop a better drug delivery system with more 
controllable release, better bioavailability, and convenient routes of use for topical 
administration of small hydrophobic ophthalmic drugs. 
    As revealed by the American Academy of Ophthalmology, millions of Americans 
suffer from eye diseases, most of which target at the posterior segment of the eye. [1] 
Some drugs have been developed to treat such eye diseases; however, it can be a 
challenge to deliver the drug to the posterior segment of the eye.  Several barriers with 
effective defense mechanisms must be breached in order to deliver drug to the posterior 
segment of the eye.  A drug delivery system to overcome these barriers was recently 
proposed and studied by a former graduate student of our research group. The proposed 
design included a thin, collagen membrane embedded with drug-loaded nanoparticles. 
Although this system was proved to deliver drug over an extended period, there was a 
sudden burst of 20 wt. % drug loading observed for the first 24 hours.  The goal of the 
present project is to improve the previous system with less initial burst and extended drug
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release. We propose to entrap the drug-loaded nanoparticles with mucoadhesive 
polyelectrolytes. The mucoadhesive coating materials will help with prolonging the 
residence time of the system as well as controlling the drug release rate. Furthermore, 
these coated nanoparticles can be easily administrated like eye drops without any side 
effects. 
1.1 Eye Anatomy, Diseases and Complications 
The eye is one of the most complicated organs in human body with many parts working 
for sense of sight. The eye is composed of the following two segments: (1) the anterior 
segment, which includes the cornea, iris, pupil, and lens, and (2) the posterior segment, 
which includes the vitreous body and retina. The main parts of the eye are shown in Fig. 
1, and typically, the retina is the target for drug delivery for many eye diseases, since this 
is the only tissue of the eye that contains major blood vessels.   
 
 
Figure. 1 –The anatomy of the eye [2] 
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    In recent years, several eye diseases have become prevalent in the United States. 
Blindness or low vision affects 3.3 million Americans age 40 and over, and this figure is 
projected to reach 5.5 million by the year of 2020. Among various vision-threatening eye 
diseases, there are four primary types, which include cataract, glaucoma, age-related 
macular degeneration (AMD), and diabetic retinopathy, all of which may lead to 
irreversible blindness. [1]  
    One common ground of the primary eye diseases is that the focus of the disease is 
located at the posterior segment of the eye, which restricts effective treatment. Cataract is 
a clouding of the lens in the eye that affects vision. Glaucoma is a group of diseases that 
damage the optic nerve and result in vision loss and blindness. The reason for appearance 
of glaucoma is still ambiguous, but is believed that eye pressure may play an important 
role in damaging the optic nerve. Age-related macular degeneration is a diseaseassociated 
with aging that gradually destroys sharp, central vision.  There are two types of AMD, 
wet AMD and dry AMD, involving abnormal development of blood vessels and light-
sensitive cells at the retina, respectively. Diabetic retinopathy is the most common 
diabetic eye disease, also caused by changes of blood vessels in the retina. 
1.2 Current Treatment Strategies for Eye Diseases 
The success of therapy to eye diseases, strongly depends on achieving sufficient drug 
concentration at target tissue for a sufficient period of time. However, for most eye 
disorders located at the posterior segment of the eye, controlled drug delivery is a major 
challenge due to the need to overcome physiological barriers.  
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    Generally speaking, there are two ways for ocular drug delivery, systemic 
administration and topical administration. The former has been used to treat a few vitreo-
retinal diseases, such as glaucoma [3] and dry eye [4]. However, a previous study showed 
that only limited quantities of about 1-2% of drug could be distributed to the eye. [5] The 
limitations are due to the blood-retina barrier, which is selectively permeable for 
hydrophobic molecules and prevents drugs from reaching the posterior segment of the 
eye. As a result, large doses are required to obtain sufficient drug concentration at the 
target sites, leading to significant peripheral side effects. On the other hand, drug 
administration in a topical route is preferred due to the ease of administration, as well as 
low cost. 
    Non-invasive treatments include eye drops, ophthalmic gels, ointments, and contact 
lenses. More than 90 % of the marketed ophthalmic formulations are in the form of eye 
drops. Conventional eye drops are easily eliminated at the precorneal area due to tear 
drainage and blinking, and actually less than 5% amount of drug can reach the posterior 
segment of the eye. Besides, eye drops provide a pulse entry of the drug, followed by a 
rapid decline in drug concentration. In other words, dosage via eye drops is inconsistent 
and difficult to regulate, rendering most of the drug released in an initial burst. In 
addition, the remainder of drug is drained into the nasal cavity, where the drug is then 
absorbed into the bloodstream. This leads to an extensive systemic absorption and may 
result in undesirable side effects. As an example, timolol  ((S)-1-(tert-butylamino)-3-[(4-
morpholin-4-yl-1,2,5-thiadiazol-3-yl)oxy]propan-2-ol, a beta blocker) in form of eye 
drops can slow the heart for at least the first six months of use. Ophthalmic gels and 
ointments are semisolid dosages developed with increased viscosity in order to prolong 
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the retention time of the drug at the precorneal area, and thus improve bioavailability. 
However, they may blur the vision significantly. Contact lenses have been used for 
ophthalmic drug delivery, because they provide a much longer residence time in the tear 
film, thereby results in higher drug flux through the cornea and reduce the drug 
elimination through bloodstream in the nasal cavity.  
    Invasive treatments, such as intravitreal injections or implants provide efficient drug 
delivery to the back of the eye, as well as reduced systemic toxicity. Frequent 
administration of drug via injection results in extreme patient discomfort and may cause 
retinal detachment, infections, and vitreous hemorrhage. [6] The long-term accumulation 
of intravitreal implants might significantly impact the patient’s vision. [6] 
1.3 Controlled Drug Delivery Systems 
Although the conventional dosage forms, such as eye drops or ointment, are not cost 
efficient to treat posterior segment diseases, noninvasive topical administrations may 
have advantages in reducing side effects, easy application and good compliance. 
Therefore, novel drug delivery systems like nanoparticles/nanosuspensions, hydrogel, 
particle-embedded contact lenses, and dendrimers have been developed for this purpose. 
    The noteworthy impact of controlled drug delivery systems is that the limitations of 
conventional delivery systems in ocular drug delivery and different barriers present inside 
the eye can be successfully overcome. Controlled drug delivery systems maintain	  the	  drug	  in	  the	  desired	  therapeutic	  range	  by	  a	  single	  administration,	  and	  offer selective 
targeting at the desired site, thus increase the efficiency of drug delivery by improving 
the release profile and also reduce drug toxicity. Ocusert, one of the earliest clinically 
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used controlled release systems was designed to improve the therapy of glaucoma. The 
Ocusert delivers pilocarpine ((3S,4R)- 3-ethyl- 4-((1-methyl- 1H-imidazol- 5-yl) 
methyl)dihydrofuran- 2(3H)-one) continuously for one week with less drug and fewer 
side effects. [7] In previous work by our research group, a thin membrane embedded with 
drug-loaded nanoparticles was characterized. The in vitro drug release test showed a 
sustained release for seven days. 
    For an excellent controlled drug delivery system for ophthalmic administration, the 
following properties are desirable. i) Extended residence time, to prolong the contact time 
of the drug delivery system at the preconeal area. ii) Improved solubility, to facilitate 
parenteral drug administration. iii) Targeting, to increase the drug concentration at 
targeted tissues and reduce systemic drug levels. iv) Controlled drug release, to maintain 
a constant therapeutic dose at the function site. v) More convenient routes of 
administration. vi) Nanoscale, to avoid any uncomfortable feelings and improve 
compliance. 
1.4 Development of a Novel Ophthalmic Drug Delivery Device 
For the present work, we propose a design of drug loaded core-shell nanoparticles as 
shown in Fig. 2. Lidocaine, a hydrophobic small molecular drug, was selected as the 
model drug, due to its representativeness of many ophthalmic drugs. Core nanoparticles 
are synthesized with PGA, since it is biocompatible, biodegradable, and with good 
potential for long-term drug delivery. With lidocaine loaded within polyglycolide cores, 
the shell was constructed by alternative deposition with negatively charged type I 
collagen and positively charged chitosan, The alternative coating, also called LbL self-
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assembly, is a promising way to produce multilayers with controllable thickness, which 
renders controllable sized nanoparticles. The alternative deposition will be repeated for 
three times to obtain three bilayers, and chitosan was designed as the outmost layer due to 
its advantageous mucoadhesive property that provides longer residence time at the 
precorneal area. Type I collagen, the most abundant protein in human body, is selected 
because it is biocompatible and weakly biodegradable. These core-shell nanoparticles are 
suitable for dry storage, and can be easily resuspended in aqueous fluid before 
administration. 
    The resulting nanoparticles were characterized. The size distribution was measured to 
show appropriate average size and deviation within nanoscale. SEM images were taken 
to confirm the size distribution, as well as to show the morphology of the nanoparticles. 
FTIR spectra indicated successful entrapment of model drug within core nanoparticles. A 
variation of zeta potential after each coating cycle confirmed layer growth and gives a 
reference of the colloidal stability of nanoparticles in suspension. Finally, in vitro drug 
release was measured over a period of 20 days. 
 
 
Figure. 2 – Details of novel ophthalmic drug delivery device 
Polyglycolide	  +Lidocaine	   Type	  I	  Collagen	  (-­‐)	   Polyglycolide	  +Lidocaine	   Chitosan	  (+)	   Polyglycolide	  +Lidocaine	  
Repeat	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CHAPTER II 
 
 
LITERATURE REVIEW 
 
Despite years of effort by many scientists and engineers, the delivery of ocular drug by 
penetrating through a few barriers is still a challenge.  Most chronic eye disorders are 
treated topically with drug in the form of conventional solutions, suspensions, and 
ointment. Administration of drug in this form suffers from rapid elimination and low 
bioavailability, due to the unique physiological structure of the eye. The main objective 
of this work is to develop an improved ocular drug delivery system to not only overcome 
solubility problem of hydrophobic drugs and drug targeting issues, but also with good 
mucoadhesive properties and controlled drug release profile.  
2.1 Anatomy of the Eye  
The eye is one of the most complicated organs in human body with many parts working 
for sense of sight. The eye is composed of the following two segments: (1) the anterior 
segment, which includes the cornea, iris, pupil, and lens, and (2) the posterior segment, 
which includes the vitreous body and retina. The main parts of the eye are shown in Fig.
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1, and functions of each part are introduced as follows. 
i. Tear film is the outmost part of the eye and is comprised of the following three layers: 
oil, water, and mucous. The lower mucous layer acts as tape, helping the tear film adhere 
to the eye. The upper oil layer prevents water evaporation. The tear film keeps the eye 
moist, creates a smooth surface for light to pass through the eye, nourishes the anterior 
segment of the eye, and protects the eye from injury and infection from exterior 
environment. 
ii. The cornea is a transparent part in front of the eye that covers the iris, pupil, and 
anterior chamber. It contains no blood vessels, and receives nutrients via diffusion from 
outside tear liquid and inside aqueous humor.  
iii. The pupil is a hole located in the center of the iris of the eye that allows light to enter 
the retina. It appears black because most of the light entering the pupil is absorbed by 
interior tissues.  
iv. The iris is a thin, circular structure in the eye that is capable for controlling the 
diameter and size of the pupils by contracting or expanding the attached muscles, and 
thus to adjust the amount of light reaching the retina.  
v. The lens is a transparent, biconvex structure in the eye. By changing shape it can 
accommodate the focal distance of the eye, and help to form a sharp image of the object 
of interest on the retina. 
vi. The vitreous humor is a transparent gel-like liquid that fills up the space between the 
lens and the retina. The vitreous humor consists of very few cells and no blood vessels. 
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Although 98-99% of its volume is water, the vitreous humor serves to maintain the 
spherical shape of the eye. 
vii. The retina is a light sensitive tissue that lines the inner surface of the eye. When light 
reaches the retina, it initiates a series of chemical and electrical impulses that trigger 
nerve signals that are sent to brain via the optic nerve. 
viii. The macula is an oval-shaped pigmented yellow spot at the center of the retina. It is 
capable to absorb excess blue and ultraviolet light that enters the eye, and help to protect 
the eye as a natural sunblock. 
ix. The optic nerve, located at the back of the eye, is a bundle of more than one million 
nerve fibers. It is used to transmit information from the retina to the brain. Its primary 
function is to relay electrical impulses to form images. 
    As shown in Fig. 3, the eye is partially isolated from the other parts of the body, as 
well as the environment by the following types of barriers: i) muco-aqueous layer of tear 
film, ii) the conjunctival and corneal epithelium, iii) the iris blood vessels, iv) the blood-
aqueous barrier, and v) the blood-retina barrier.  
    The barriers described above make the eye highly defensive to foreign substance, and 
drugs are no exception. Drugs are mainly eliminated from the precorneal lacrimal fluid 
by solution drainage, lacrimation and nonproductive absorption to the conjunctiva of the 
eye. [8] For example, blinking and tear drainage through lachrymal drainage system 
remove topically applied drug within 30 seconds.  The drug transport through corneal 
epithelium is essentially via paracellular or transcellular route. Hydrophilic drugs 
penetrate mainly through the paracellular pathway while hydrophobic drugs prefer the 
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transcellular route. Other factors, including solubility, molecular weight, shape, charge, 
and degree of ionization, also affect the route and rate of penetration through cornea. [8] 
Particulate nanocarriers have been reported to follow the endocytic pathway. [9] One of 
the maintenance strategies of the corneal transparency can be tight cell junction, which 
renders the interior part of the eye nearly impermeable to any macromolecules larger than 
500 Da. [10] 
 
 
Figure. 3 –Physiological barriers of the eye [2] 
 
2.2   Controlled Ocular Drug Delivery 
Controlled drug delivery to the eye is one of the most challenging fields of ophthalmic 
research. Low drug-contact time and poor bioavailability due to precorneal elimination 
are problems associated with conventional systems. In addition, anatomical barriers and 
physiological conditions of the eye also confine effective topical drug delivery. Therefore, 
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novel drug delivery systems like nanoparticles/nanosuspensions, hydrogel, drug-loaded 
contact lenses, and dendrimers have been developed for this purpose. 
2.2.1 Ophthalmic Hydrogels 
In order to avoid the rapid dilution and elimination, eye drop formulations with an 
increased viscosity have been developed. Hydrogels are three-dimensional hydrophilic 
macromolecular networks containing large amount of water within their structure. The 
soft, insoluble properties are similar to natural tissue, which leads to wide applications in 
biomedical and pharmaceutical area. These formulations may contain various viscosity 
enhancing agents, such as poly(vinyl alcohol), poloxamer (a series of nonionic triblock 
copolymers), methyl cellulose, and carbopol (prop-2-enoic acid), and the drug is 
generally loaded throughout the formulation.  
    The drug release from hydrogel systems follows three mechanisms, diffusion control, 
chemical control, and swelling control. In diffusion-controlled systems, the drug can be 
dissolved or dispersed in the polymer, and then diffused driven by a gradient in 
thermodynamic activity. In chemical-controlled systems, the therapeutic agent is released 
by hydrolysis or enzymatic degradation of the polymer. In swelling-controlled systems, 
the influx of water in the hydrophilic polymer matrix and consequent swelling of the 
system controls the release of the drug. [11] The use of hydrogel in ocular topical 
administration can provide an enhanced bioavailability of drug as the residence time is 
significantly prolonged. 
    Gelation of hydrogels can occur when stimulated by environmental factors like 
temperature, pH and ionic strength.  The in-situ gelling system is a free flowing liquid at 
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room temperature, allowing easy drop-wise administration into the eye. Upon exposure 
tophysiological environments, the gel will undergo phase transition from liquid to a 
semisolid gel, which increases the mechanical strength of the system. Both 
thermosensitive polymers like poloxamer, and pH sensitive polymers like carbopol have 
been employed to develop in-situ gelling systems. [12]-[14] Mansour et al. [15] 
developed poloxamer-based in-situ gelling formulations of ciprofloxacin hydrochloride. 
The sol-gel transition temperature ranged from 28.00 to 34.03 °C, and the prepared 
formulae showed improved ocular bioavailability compared with the marketed 
conventional eye drops. Wu et al. [16] designed an in-situ pH triggered gelling system to 
improve the stability and bioavailability of baicalin, an anti-inflammatory and anti-
cataract drug. Carbopol 974P was used as the gelling agent, and sol-gel transition 
occurred at pH 6.0. The formulation provided sustained release over eight hours. Gupta et 
al. [17] employed chitosan (a pH-sensitive polymer) in combination with gellan gum (an 
ion-activated polymer) to develop a gelling system. The gelation required pH 6.5 to 7.0 
and osmolarity of 298 to 302 mOsmol, which is very close to physiological conditions. 
    With improved mechanical and mucoadhesive properties, the ophthalmic gels can 
prolong the retention time of the drug at the precorneal area, and thus improve 
bioavailability. However, gels may blur the vision. For some pH sensitive polymers, such 
as carbopol, an acidic pH is required before phase transition. This formulation may cause 
irritation to the eye tissue, and increases lacrimal secretion, which drains the formulation 
more quickly. [14] 
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2.2.2 Nanoparticles 
During past decades, research on nanotechnology has gained extensive concerns, and has 
been applied in various biomedical areas, such as drug delivery, gene therapy, and 
diagnostics. With applications of nanotechnology in drug delivery systems, hydrophobic 
drugs, peptides, and proteins, can be delivered precisely to targeted sites.  
    Properly formulated drug loaded nanoparticles (DNPs), such as a colloidal system, can 
be a promising approach for ophthalmic drug delivery. A colloidal system is suitable for 
drugs with poor solubility in water. Dispersion of DNPs in a suitable solvent provides an 
easy dropwise application in liquid form just like regular eye drops. DNPs in eye drops 
can avoid discomfort associated with administrations of viscous or sticky preparations, 
such as ointment, which leads to blurry visions. Furthermore, it is possible for the 
particles to be retained in the ocular cul-de-sac for extended duration after topical 
administration, as well as sustained drug release. This makes DNPs more patient friendly 
as an additional advantage.  
    Nanoparticles with sub-micron properties differ from macroscopic objects in several 
aspects, such as high surface area to volume ratio, energy, and Brownian motion in liquid 
media. The reduced size of the particles helps with the adsorption and permeation 
through the ocular barriers. The reduced size also ensures patients will not experience 
abrasion to their eyes. There are many factors that have an influence on the drug release 
and degradation of the nanoparticles, including the size, morphology, physical state of the 
encapsulated drug, and molecular weight and crystallinity of the polymer. Measuring 
Zeta potential of the particles provide information about the surface charge, which 
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determines the stability of the colloidal system. Adequately high zeta potential values 
beyond +/- 30 mV are considered to be a stable colloidal dispersion.  
    Biodegradable nanoparticles for pharmaceutical use can be prepared from various 
synthetic and natural polymers. Some synthetic polymers are like polyacrylates, 
poly(lactide-co-glycolide), and polycaprolactones. Pignatello et al. [18] developed 
flurbiprofen (FLU) loaded acrylate polymer nanosuspensions for ophthalmic application. 
The incorporation of drug in the polymer nanoparticles enhanced FLU the availability at 
an intra-ocular level for the prevention of the myosis induced during extracapsular 
cataract surgery. Gupta et al. [20] developed a colloidal system with sparfloxacin (a 
newer-generation hydrophyobic fluoroquinolone used in bacterial conjunctivitis) loaded 
PLGA nanoparticles to improve precorneal residence time and ocular penetration. 
Lacoulonche et al. [21] investigated the stability and in vitro release of FLU loaded poly-
ε-caprolactone nanospheres. Natural polymers including albumin [24], alginate, gelatin 
[26], and chitosan [27] have also been used as nanocarriers. Kang et al. [25] reported a 
study on in vitro release of FITC-dextran (a dye, Mw 40,000) from alginate beads. They 
found that amaranth (a deep red dye) could be released for six hours with a first order 
profile. Wu et al. [28] were able to develop chitosan nanoparticles with excellent capacity 
for ammonium glycyrrhizinate, and the in vitro release test showed an obvious burst 
followed by a slow and continuous release phase. 
    Particle fabrication techniques include precipitation/coacervation, spontaneous 
emulsification/solvent diffusion, salting out/emulsification-diffusion, ionic gelation, and 
desolvation. Kakran et al. [30] prepared artemisinin ((3R,5aS,6R,8aS,9R,12S,12aR)-
octahydro-3,6,9-trimethyl-3,12-epoxy-12H-pyrano[4,3-j]-1,2-benzodioxepin-10(3H)-one, 
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ART) nanoparticles by the precipitation method. Original ART powder was dissolved in 
a good solvent (ethanol), and then nanosuspension was formed by quickly adding an 
antisolvent (hexane). Then nanoparticles were recovered by evaporating the good solvent 
and antisolvent. El-Shabouri [31] reported chitosan NP preparation by the 
emulsification/solvent diffusion method. An oil-in-water emulsion was obtained upon 
injection of an organic phase into chitosan solution containing a stabilizing agent under 
mechanical stirring, followed by high-pressure homogenization. The emulsion was then 
diluted with a large amount of water, whereupon polymer precipitation occurs as a result 
of the diffusion of organic solvent into water, leading to the formation of nanoparticles. 
This method is suitable for high drug entrapment of hydrophobic drugs. The major 
drawbacks of this method are harsh processing conditions (e.g., the use of organic 
solvents) and the high shear forces used during nanoparticle preparation. Janes, et al. [32] 
fabricated doxorubicin (DOX) loaded chitosan nanoparticles by ionic gelation. The 
mechanism is based on electrostatic interaction between positive charge amine group of 
chitosan and negative charge group of a polyanion. DOX was first incubated with 
tripolyphosphate (a polyanion), and then added to a chitosan solution with acetic acid. 
Nanoparticles were formed upon mechanical stirring at room temperature. This process is 
simple with mild condition. Jun et al. [33] developed protein loaded bovine serum 
albumin (BSA) nanoparticles with the desolvation method. Protein and BSA were 
dissolved in an aqueous solution and stirred. A desolvating agent, acetone, was added 
dropwise to the stirring aqueous solution, thereby forming the nanoparticles.  
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2.2.3 Dendrimers 
Dendrimers are macromolecular compounds made up of a series of branches around a 
central core [36], and the drug payload can be physically entrapped within the dendrimer 
or chemically attached to the surface [37]. Dendrimers can deliver drug with better water-
solubility, bioavailability and biocompatibility and have successfully explored for 
different routes of drug administration. Poly(amidoamine) (PAMAM) dendrimers for 
delivery of pilocarpine nitrate and tropicamide (N-ethyl-3-hydroxy-2-phenyl-N- (pyridin-
4-ylmethyl) propanamide) were developed by Vandamme and Brobeck [38]. They found 
that residence time was longer for the solutions containing dendrimers with carboxylic 
and hydroxyl surface groups. In another study, Yao et al. [39] prepared and evaluated 
puerarin (one of several know isoflavones) -dendrimer complex as an ocular drug 
delivery system. Puerarin-dendrimer led to longer residence time in rabbits compared 
with puerarin eye drops.  
2.2.4    Drug-loaded Contact Lenses 
Contact lenses have been used for ophthalmic drug delivery. Traditionally used soaked 
contact lenses provide a drug release for a few hours. Current challenges in this mode of 
drug delivery are to sustain release for longer period and also to incorporate sufficient 
drug amounts in the lens matrix. Lens provides a much longer residence time in the tear 
film, thereby results in higher drug flux through the cornea and reduce the drug 
elimination through bloodstream in the nasal cavity. 
    One type of soft contact lens can absorb a number of drugs when presoaked in the drug 
solution, and then release them into the post-lens lacrimal fluid. Alternatively, soft 
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contact lenses can be placed into a patient’s eyes then drug-containing eye drops are 
applied. The drug can be absorbed and released by the soft contact lens, minimizing 
clearance and sorption through the conjunctiva. [40] 
    However, soft contact lenses do come with some disadvantages. For one, the content of 
drug loading by presoaking lenses in the drug solution is limited. [40] Therefore, lenses 
can only deliver drugs for a few hours. The residence time of a system could be 
lengthened by suspending nanoparticulate based drugs in contact lenses, which is similar 
as Mr. Sharma’s design of nanoparticle embedded membrane. Another limitation is that it 
requires patients to wear the contact lens at all times. [41] 
2.2.5   Implants 
Ocular implants provide a platform for sustained release of molecules from either 
biodegradable or non-biodegradable polymeric matrices over several months to years. 
The implants can either be deposited into the vitreous body or sutured on the sclera as 
shown in Fig. 4. For example, Alginate coated implants of growth factors (epidermal) 
showed promising applications in ocular therapy of keratitis sicca. [42] 
    The design of implants involves drug solubility, diffusion coefficient of the drug in the 
polymer, drug loading capacity, and the degradation rate of the polymer. 
Biocompatibility is essential to all components, which are required to be chemically inert, 
noncarcinogenic, hypoallergenic, and mechanically stable at the implantation site.  
    Although the ophthalmic implants are able to provide sustained release of drug, the 
high-density formulations deposited on the inferior retina may lead to local adverse 
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effects. In addition, the long-term accumulation of intravitreal implants might 
significantly impact the patient’s vision. [6] 
 
 
Figure. 4 –Schematic presentation of intravitreal route of drug delivery to posterior 
chamber of the eye. (A) Intravitreal injection through a needle. (B) Biodegradable or non-
biodegradable implants introduced into the vitreous body. (C) Scleral plugs or implants 
sutured onto the sclera. [6] 
 
2.3 Layer-by-Layer Assembly for Drug Delivery 
Layer-by-Layer (LbL) assembly is an approach to construct a multilayers, by consecutive 
deposition of complementary and interacting polymers onto some template, taking 
advantage of interlayer force as shown in Fig. 5. The template can be particles, planes, 
tubes, and any irregular shapes. [43] Zheng et al. [44] made polyelectrolyte-coated 
minimal in the midvitreous space and only infinitesimal concen-
trations are present at the anterior vitreous, closer to the ciliary
body [12,13]. This well-regulated convective flow within the vis-
coelastic gel structure of the vitreous is disrupted with liquefaction
and vitrectomy, leading to significant changes in the diffusion
coefficient of administered drugs [10]. The density of a given
formulation might also affect the distribution within the vitreous,
with high-density formulations depositing on the inferior retina
causing localized adverse effects. In addition, the long-term accu-
mulation of intravitreal implants might significantly impact the
vision of patients [11].
The inner limiting membrane (ILM) and the BRB are the main
biological barriers to drug transport from the vitreous to the retina.
The ILM forms a border between the vitreous humour and the
retina and is the primary barrier to drug diffusion to the retina [14].
The BRB, which is composed of the endothelial cells of retinal
blood vessels and the retinal pigmented epithelium (RPE), forms
the secondary barrier to the transport of lipophilic drugs to the
inner retinal cells. Studies have shown rapid clearance of lipophilic
molecules administered into the vitreous by passive diffusion via
the BRB. Furthermore, the efflux transporters in the endothelium
lead to rapid elimination of molecules that are substrates for this
innate active transport mechanism [15].
Present evidence therefore suggests that, although the intravi-
treal route is useful in attaining high drug concentrations at the
retina, it is not the ultimate strategy for drug delivery to the
posterior ocular tissue.
Periocular routes
The periocular route of drug delivery enables the deposition of
molecules against the external surface of the sclera, thereby mini-
mizing the risk of endophthalmitis and retinal damage associated
with the intravitreal route of administration [16,17]. It is consid-
ered to be the least painful and the most efficient route of drug
delivery to the posterior eye [1,18–24]. Periocular pathways used
for the delivery of drugs to the posterior tissues of the eye include
the retrobulbar, peribulbar, subtenon and subconjunctival routes
(Fig. 2).
Both the subconjunctival and the subtenon routes are widely
used in research into transscleral drug delivery owing to their
proximity to the sclera. With subconjunctival injection, the for-
mulation is placed beneath the conjunctival membrane that cov-
ers the sclera. This enables the drugs to bypass the conjunctiva–
cornea barrier, giving direct access to the transscleral route. Sub-
tenon injection involves the placement of a formulation between
the sclera and Tenon’s capsule, an avascular membrane. As such,
the contact time between the administered drug and the sclera is
prolonged. Consequently, the subtenon route is considered to be
one of the most promising routes for targeting the posterior
segment of the eye [1,25].
The direct penetration pathway is the main route in achieving
high concentrations of a drug in the vitreous following subtenon
injections [26–28]. The sclera, with its large surface area (16.3 cm2),
is less resistant to permeation of molecules and has lower protease
activity compared to the cornea [29,30]. However, there are a few
static and dynamic barriers to transscleral drug delivery.
Scleral permeability depends on the molecular radius rather
than the molecular lipophilicity [31] and molecules of up to
70,000 Da can readily penetrate the sclera [31–35]. It also depends
on scleral hydration and intraocular pressure; however, the latter
has negligible effects at normal intraocular pressures (15–
20 mmHg) [23,24]. Nevertheless, only minute concentrations of
a drug administered via the transscleral route end up in the
vitreous [36,37]. This low bioavailability can be attributed to
the loss of the drug from the periocular space, BRB, choroidal
REVIEWS Drug Discovery Today ! Volume 16, Numbers 5/6 !March 2011
[()TD$FIG]
FIGURE 1
Schematic presentation of the intravitreal route of drug administration to the
posterior eye. (a) Micro- or nanoparticl s injected using a needle. (b)
Biodegradable or non-biodegradable implants surgically introduced into the
vitreous. (c) Scleral plugs or implants sutured onto the sclera.
[()TD$FIG]
FIGURE 2
Schematic representation of the periocular routes of drug administration.
272 www.drugdiscoverytoday.com
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nanoparticles with curcumin ((1E,6E)-1,7-Bis(4-hydroxy-3-methoxyphenyl)-1,6-
heptadiene-3,5-dione) crystal as a template. The drug release sustained up to 20 hours. 
Various materials can be used in self-assembly, including polymers, biomaterials, and 
inorganic species, and various interlayer forces can be employed when building 
multilayers. Electrostatic interaction, hydrogen bond, covalent bond, metal coordination, 
and bio-specific recognition have already been demonstrated successfully.  Zhou et al. 
[45] deposited two natural polysaccharides, chitosan and alginate, by LbL assembly on 
PLGA nanoparticles for antifouling protection. The deposition was based on electrostatic 
interaction between the two polymers. Uttam et al. [46] constructed LbL assembly based 
on hydrogen bonding between DNA base pairs (adenine and thymine). Chitosan modified 
with adenine interacted with hyaluronic acid modified with thymine. Mu et al. [47] 
fabricated multilayer microcapsules via covalent LbL assembly. The covalent bonding 
occurred between the amino groups of chitosan and the aldehyde groups of oxidized 
sodium alginate. Wanunu et al. [48] achieved LbL growth of multilayer via metal-organic 
coordination using Zr4+ ions. Hoshi et al. [49] prepared thin films by LbL deposition 
taking advantage of a strong bioaffinity between concanavalin A (a carbohydrate-binding 
protein) and sugar chains attached to the surface of avidin (a biotin-binding protein). 
Among different strategies, covalent crosslinking has the best stability.  
    The capability of successive layer growth gives a freedom in both the number of layers 
and layering sequence. For different situations, variation of the shell thickness within 20 
to 100 nm allows the release time to vary from several minutes to a few weeks. Ye et al. 
[51] were able to construct thickness about 13 nm and five bilayers of chitosan and  
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Figure. 5 - Layer-by-Layer (LbL) assembly of polyelectrolytes on particles. (a) Particles 
with an inherent charge are incubated in a solution of oppositely charged polyelectrolytes. 
(b) Following centrifugation/ rinsing steps to remove excess polyelectrolyte, the coated 
particles exhibit charge reversal, which facilitates the adsorption of another layer of 
oppositely charged polyelectrolyte. (c) The process is repeated until the desired number 
of layers/ thickness is achieved. (d) The particle templates can be subsequently removed 
to yield polyelectrolyte capsules. [50] 
20 Chem. Soc. Rev., 2011, 40, 19–29 This journal is c The Royal Society of Chemistry 2011
metal–ligand complexation11 to prepare multilayer films. Such
versatility allows a diverse range of materials to be assembled
into thin films, including synthetic or biological polymers
(charged and/or uncharged), inorganic or metal nanoparticles,
proteins and small molecules. Furthermore, LbL assembly can
be adapted to a range of substrates/templates with different
compositions and morphology, including membranes, fibres
and particles (Fig. 1).12 The LbL assembly of materials on
particles and the subsequent formation of capsules13,14 are of
particular interest, principally because of the promise of these
carrier particles in therapeutic delivery applications.15 A main
feature of LbL assembly is that the properties of the resulting
materials—films or capsules—can be precisely tuned by con-
trolling the assembly conditions, the materials adsorbed at
each layer, and subsequent processing steps for stabilisation
and functionalisation. The expectation that such materials will
find increasing application in biomedicine is only now starting
to emerge.15–18 In this tutorial review, we highlight recent
advances in the assembly and engineering of hydrogen-bonded
films/capsules. We focus on hydrogen-bonded systems9
because they can be designed to exhibit stimuli-responsive
properties under physiologically-relevant conditions, and
allow the incorporation of uncharged polymers, which is
important for developing stealth materials. We highlight the
loading and release of therapeutic cargo from these materials
with special emphasis on the application of these systems for
drug/gene delivery, both in vitro and in vivo.
2. Layer-by-layer film assembly
2.1 Background
One of the key advantages of the LbL technique is the
precision with which each layer of the film can be engineered.
This can be achieved by varying either (a) the materials used,
(b) the number of layers deposited, or (c) the conditions of
deposition.7 For example, in charged polymer (polyelectrolyte)
systems, increasing the salt concentration can significantly
affect the thickness and density of the films, as the salt ions
shield the polyelectrolyte charges, leading to a more coiled
polyelectrolyte conformation and thicker layers.19 In the case
of weak (i.e., pH-dependent) polyelectrolytes, film thickness
and morphology can be tuned by both the salt concentration
and pH.20 While there are many useful studies based on
multilayers assembled from opposit ly charged polyelectrolytes,18
it is challenging to design materials that are responsive within
Fig. 1 Layer-by-layer (LbL) assembly of polyelectrolytes on
particles. (a) Particles with an inherent charge are incubated in a
solution of oppositely charged polyelectrolyte. (b) Following several
centrifugation/rinsing steps to remove excess polyelectrolyte, the
coated particles exhibit charge reversal, which facilitates the
adsorption of another layer of oppositely charged polyelectrolyte.
(c) The process is repeated until the desired number of layers
(and hence thickness) is achieved. (d) The particles can be sub-
sequently removed to yield polyelectrolyte capsules.
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sodium alginate on monodisperse polystyrene, and obtained a sustained release of 
acridine hydrocholoride (a hydrophilic drug, Mw 215.68) up to five hours. 
    The construction of multilayers in an LbL manner has several favorable features. First, 
the surface properties may be tailored by selecting materials suitable for specific purposes. 
For example, to use a positively charged material as the outmost layer will offer better 
mucoadhesive property, because the mucosa is negatively charged. [52] Second, the LbL 
assembly process is usually performed with simple operations in aqueous medium at 
room temperature, and does not require harsh conditions. Therefore, it becomes possible 
to apply biomaterials, such as polysaccharides and proteins without changing the 
chemical structure or specific bioactivity.  
2.4 Selection of Biodegradable Polymers 
2.4.1 Core Material 
Polyglycolide (PGA) is a linear, semi-crystalline aliphatic polyester, as shown in Fig. 6. 
It is non-toxic and biodegradable in the human body, and has good mechanical strength. 
Consequently, this polymer has found many applications in the biomedical area, such as a 
wound closure material, a surgical suture, and a tissue engineering scaffold. Previous 
research also revealed its potential in drug delivery. Hurrell and Cameron [53] developed 
a drug-loaded 3D matrix by incorporating a small molecule hydrophobic model drug, 
theophylline (a small hydrophobic drug, Mw 180.16), into polyglycolide, and reported a 
sustained release for 20 days.  
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Figure. 6 – Chemical structure of polyglycolide 
 
    The degradation of PGA is a complicated process. Generally, it degrades in the 
presence of water by a hydrolysis reaction at the ester backbone, which is acid catalyzed 
and reversible. Hurrell and Cameron [54] proposed a four-stage reaction-erosion front 
model. In stage I, which occurs over the first a few hours after immersion, water diffuses 
into the polymer matrix homogeneously and scission of the chains by hydrolysis begins 
as the polymer contacts water. During stage II, little water is absorbed and subsequent 
hydrolysis of the polymer continues. During this stage very little mass is lost, because the 
chains are still too large to diffuse from the polymer matrix. In stage III, some oligomers 
are small enough to dissolve into the media, and a reaction-erosion front forms, 
separating the central autocatalyzing region from the surface where the oligomers diffuse 
out. As oligomers escape, space is created to allow for more water to come in, drug is 
released rapidly, and the reaction-erosion front moves towards the sample center. At the 
beginning of stage IV, the front meets the sample center, and drug release is completed. 
Fig. 7 shows drug release for the four-stage degradation process. 
    Although polyglycolide shows a convenient timescale of degradation, is semi-
crystalline in nature, biocompatible, and excellent drug loading efficiency, it is seldom 
investigated to fabricate drug-loaded nanoparticles due to its difficulty in handling. 
	  24	  
 
Figure. 7 – The relationship between drug release and the four-stage degradation process 
[55] 
     
2.4.2 Shell Material – Type I Collagen and Chitosan 
Desired shell properties include good biocampatibilty, as well as good mucoadhesive 
property. The following two oppositely charged, biodegradable materials were chosen to 
fabricate the shell by the layer-by-layer method:  type I collagen and chitosan.  
    Collagen is composed of a triple helix, which generally consists of two identical chains 
and an additional chain slightly different in its chemical composition. Type I collagen is 
the most abundant protein present in mammals.  Collagen is the major component of the 
extracellular matrix and serves as a natural substrate for cell attachment. Consequently, 
collagen has been widely used for wound dressing, which was approved by the US Food 
and Drug Administration (FDA). Collagen undergoes enzymatic degradation within the 
body via enzymes, such as collagenases and metalloproteinases, to yield corresponding 
amino acids. Fathima et al. [59] tested the degradation time of collagen fibrils in vitro at 
J. Braunecker et al. / International Journal of Pharmaceutics 282 (2004) 19–34 21
Fig. 1. The relationship between the drug release profile and the four-stage degradation process (Hurrell and Cameron, 2003; Hurrell
et al., 2003a).
Milroy, 2001) and reported that the time of the on-
set of stage III, when the reaction–erosion fronts were
formed, was not influenced by the sample size. Conse-
quently, drug release fromPGAdisks of different thick-
ness started at the same time and released at the same
rate but finished at earlier time for thinner samples.
These trends indicated that the start of front progres-
sion, which controls the start and rate of drug release,
is independent of thickness. However, drug release fin-
ishes at earlier times in thinner samples because the
fronts have further to penetrate into the sample form
the surface before meeting in the centre. By introduc-
ing pores to the structure, the distances for diffusion
and front movement are effectively changed and the
degradation and drug release are expected to change
accordingly.
The molecular weight will also affect the degra-
dation and drug release. The reaction–erosion fronts
are not formed until a critical molecular weight is
reached whereupon some oligomers become soluble.
This behaviour suggests that a higher initial molec-
ular weight should delay the onset of stage III. On
the other hand, if the molecular weight is very low at
around 4000 gmol−1, drug release occurs over a few
hours rather than days, suggesting that the polymer is
solubilised immediately (Moll and Ries, 1991). These
results not only suggest that the effect of molecular
weight is non-linear, but also that interesting effects
could occur if a bimodal molecular weight distribution
is introduced.
2. Methods and materials
Sodium chloroacetate (98%) and sodium chloride
were obtained from Aldrich. Theophylline and phos-
phate buffered saline tabletswere obtained fromSigma.
DSC aluminium pans were purchased from TA Instru-
ments.
PGA of four different molecular weights were used
to make the samples studied in this research. Table 1
shows the molecular weight for each type. Molecu-
lar weights were determined by gel permeation chro-
matography in hexafluoroisopropanol (HFIP) kindly
perform d by Smith and Nephew Limited. To do this, a
thermal characterisation for each type of PGAwas per-
formed using DSC. Samples were heated from 20 ◦C
to 250 ◦C at 200 ◦Cmin−1, then held at 250 ◦C for
2min and rapidly cooled in liquid N2 to make them
amorphous and therefore soluble in HFIP, where they
were left to dissolve overnight. Samples were filtered
through 0.45!m PTFE filters prior to analysis. The
calibration was carried out versus PMMA calibrants,
supplied by Polymerlabs. The results are therefore ex-
pressed as PMMA molecular weight equivalents.
The notation used in this paper refers to the samples
with the codePGA(x k)where x is themolecularweight
of the polymer in thousands, rounded to the nearest
thousand (Table 1).
PGA (6 k) was made by heating sodium chloroac-
etate at 150 ◦C in an oven for approximately 20 h. The
material was spread thinly over a Petri dish during re-
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37°C and treated with collagenase, which took 96 hours for 96% weight loss. They also 
found that native collagen underwent a hydrothermal shrinkage at 62 ± 1 °C. Rudakova 
and Zaikov [60] studied degradation of collagen thread in aqueous H2SO4 and KOH 
solutions. Obscure weight loss occurred at 40 °C and above in 0.1 N H2SO4, and at 30 °C 
and above in 0.1 N KOH. Without being treated with enzymes, thermal heat, and strong 
acid or alkali, collagen is quite stable in aqueous solutions. Collagen is an 
electrochemically inert protein with an isoelectric point at 5.5, which means it carries a 
net negative surface charge at pH 7.0. Some researchers take advantage of this property, 
and fabricate layer-by-layer films with collagen. Miao et al. [61] assembled collagen with 
electroactive myoglobin into layer-by-layer films on solid surfaces.  They treated the 
solid template alternately with collagen aqueous dispersions and myoglobin solutions (pH 
5.0, since isoelectric point for myoglobin is 6.8).  UV-Visible light spectroscopy and 
cyclic voltammetry was used to confirm the film growth. Also, the thickness of the 
collagen film was investigated. Zhang et al. [62] estimated the type I collagen film as 20-
30 nm for collagen/ hyaluronic acid film by Atomic force microscopy (AFM).  
    Chitosan is a linear polysaccharide and non-toxic in oral administration approved by 
FDA. Chitosan has a similar degradation pattern to that of collagen, and undergoes 
enzymatic hydrolysis in vivo with enzymes, such as lysozyme. A study showed that it 
took one to two months for chitosan microparticles (500 ± 150 µm) to degrade 
completely in vitro at 37°C and treated with lysozyme and NAGase. [63] When 
dissolving in week acidic solutions, chitosan is charged with a high density of cations, 
which provides it with potential in layer-by-layer fabrication. The strong positive charge 
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also makes chitosan as a quite effective mucoadhesive polymer due to strong interaction 
with a negatively charged mucous membrane. [64]  
2.5 Selection of Model Drug 
Many ophthalmic drugs have chemical properties in common. As shown in Table. 1, N-
acetylcarnosine (NAC) for treating cataract, metipranolol and timolol for treating 
glaucoma, lidocaine for ocular surface anesthesia, are all small molecules drugs with poor 
solubility in water. This makes them difficult to be delivered by using aqueous eye drops. 
To achieve better solubility, the molecules need to be conjugated with acids to form salts. 
For example, metipranolol hydrochloride and lidocaine hydrochloride are hydrophilic, 
thus easily soluble in water. But for some cases where conjugation is not available, or the 
drug efficacy is compromised due to the conjugation, the drug will not be able to deliver 
in forms of conventional eye drops. 
    Lidocaine was selected as the model drug in this research based on its physical and 
chemical properties. Its formula is C14H22N2O, and molecular weight is 234.24 g/mol. 
Lidocaine was first synthesized by a Swedish chemist Nils Löfgren in 1943, and is used 
widely as a local anesthetic agent. 
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Table. 1 – Chemical structures of some ophthalmic drugs 
Name	   Chemical	  Structure	   Molecular Formula Molecular Weight 
N-acetylcarnosine 
 
C11H16N4O4 268.27 
metipranolol 
 
C17H27NO4 309.40 
timolol 
 
C13H24N4O3S 316.42 
lidocaine 
 
C14H22N2O 234.34 
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CHAPTER III 
 
 
MATERIALS, EQUIPMENT AND METHODOLOGY 
 
3.1 Chemical Reagents 
Polyglycolide (PGA, Purasorb PG20, intrinsic viscosity midpoint 1.4 dl/g) was donated 
by Purac Biomaterials (Netherland). Purified bovine type I collagen solution (PureCol, 97% 
purity, 3.1 mg/ml, pH~2) was purchased from Advanced Biomatrix (San Diego, CA). 
Chitosan was purchased from FMC BioPolymer (Philadelphia, PA). Phosphate buffer 
saline solution (PBS, pH 7.4) was prepared from salt that that was purchased from 
Invitrogen (Grand Island, NY). 1, 1, 1, 3, 3, 3-hexafluoro -2-propanol (HFIP, ≥99%), and 
dimethyldidodecylammonium bromide (DMAB, 98%) were purchased from Sigma-
Aldrich (St. Louis, MO). 2-diethylamino-N-(2, 6-dimethylphenyl) acetamide (Lidocaine, 
USP) was purchased from Spectrum (Gardena, CA). Acetonitrile (HPLC grade) and 
dichloromethane (HPLC grade) were purchased from Pharmaco (Brookfield, CT). 
Hydrochloric acid (36.5 - 38%) was purchased from EM Science (Gibbstown, NJ). 
Sodium hydroxide (99.2%) and sodium chloride (100.0%) were purchased from Fisher
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Scientific (Fair Lawn, NJ).  All chemicals were used as purchased.  Water was type I 
ultrapure.  
3.2 Equipment 
Lindberg/Blue M Box Furnace, Fisher Scientific Thermix Stirring Plate Model 210T, 
Fisher Scientific Sonic Dismembrator Model 500 with 1/2” flat probe, RC5C Centrifuge 
from Sorvall Instruments from Dou Pout Corporation, Thermo Fisher Scientific Signature 
Ultra-Low Temperature Freezer, ATR FD 3.0 freeze dryer from Appropriate Technical 
Resources, Nalgene Oak Ridge Centrifuge Tubes (50 ml), Nalgene Cryo 1 °C Freezing 
Container, Brookhaven Zeta PALS (particle analyzer based on dynamic light scattering), 
FEI Quanta 600 Field Emission Gun Environmental Scanning Electronic Microscopy 
(SEM), Shimadzu UV-1201 UV-Vis Spectrophotometer, Perkin Elmer Spectrum System 
2000 FTIR Spectrometer.  
3.3 Synthesis of Lidocaine-Loaded Polyglycolide Nanoparticles 
PGA was removed from refrigerator and allowed to stand for approximately one hour to 
come to room temperature. PGA was allowed to come to room temperature prior to 
opening in order to avoid any moisture that might accumulate on the cold powder due to 
condensation.  As donated, the PGA is a semi-crystallized, hard solid with a slightly 
yellow and opaque color.  Its elevated degree of crystallinity, around 45-55%, results in 
insolubility in most organic and inorganic solvents. To achieve solubility, PGA was heat 
treated to become amorphous. Since the melting point of PGA was reported at 227 – 
230 °C, a furnace was heated by 10 °C/ min from room temperature to 235 °C and 
stabilized. PGA was placed in a stainless steel container and heated for two minutes to 
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melt, then immediately quenched with liquid nitrogen (approximately -80 °C). The 
heating process was limited to a short period to avoid thermal decomposition of the 
polymer. [76] The resulting amorphous PGA appeared yellow and transparent.  
    In this work, an emulsion-evaporation method was employed to fabricate drug-loaded 
nanoparticles. The process involves two solutions. An organic solution was prepared in a 
50 ml amber sample bottle with cap to avoid possible heating up by sunlight, because the 
organic solvent is highly volatile. At room temperature, 100 mg of PGA and 500 mg 
lidocaine was dissolved in 40 ml HFIP and stirred on a stir plate for four hours to get a 
homogeneous solution. In a 300 ml beaker, 2000 mg DMAB was dissolved in 200 ml DI 
water and stirred for two hours to form a 1% w/v aqueous solution. Afterwards, the 
aqueous phase was placed on an ice-water bath with the tip of sonicator probe inserted 
half the liquid height. With sonication at 90% intensity (the max power is 400 w, 20 kHz), 
the organic phase was added dropwise with a pipette within one minute, thereby forming 
the nanoparticles. No additional time for sonication. The mixture was stirred for 10 hours 
to evaporate most of the organic solvent.  
     The suspension of nanoparticles was collected in six 50 ml centrifuge tubes, and 
centrifuged at 12,000 rpm at 4 °C for 20 minutes. The supernatant was substituted with 
40 ml fresh DI water.  The nanoparticles were re-suspended and centrifuged. The steps of 
rinse and centrifugation were repeated six times to remove DMAB. Finally, the 
nanoparticles were suspended in 15 ml fresh DI water and distributed evenly into 15 pre-
weighed and pre-marked 2 ml vials. These vials were placed inside an isopropanol-
jacketed container (Nalgene Cryo 1 °C Freezing Container) and deposited in an -86 °C 
freezer for ten hours. The container was used to freeze the suspension slowly at a rate of -
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1 °C/min, which prevents unwanted agglomeration of the particles. The resulting frozen 
suspension of nanoparticles was lyophilized (freeze dried) for 12 hours with the freeze 
dryer. The dried nanoparticles in the vials were weighed and used for characterization, 
further layer-by-layer entrapment, and test of drug release. 
3.4 Layer-by-Layer Assembly 
Two oppositely charged polyelectrolytes were employed to build the shell layers. 
Collagen solution was prepared by diluting Type I collagen in 0.5 M NaCl aqueous 
solution to get a concentration of 0.3 mg/ml. The solution was adjusted to pH ~ 8 with 
0.1 NaOH (aq.) with stirring on an ice-water bath. At this pH, type I collagen carries a net 
negative charge, since it is a protein with isoelectric point at pH 5.5. [77] The ice-water 
bath was used to avoid gelation of the collagen solution. Chitosan was dissolved in a 0.5 
M NaCl aqueous solution to get the same concentration of 0.3 mg/ml. A 0.1 M HCl (aq.) 
was used to adjust the chitosan solution to pH ~ 3 at room temperature. At this pH, 
chitosan was given a positive surface charge due to its pKa value ~ 6.1. [78] The two 
solutions were stirred for two hours to ensure that they were well mixed. 
    Core nanoparticles (100 mg) were suspended in 30 ml of the collagen solution and 
deposited for 20 minutes without stirring to obtain the first layer. The resulting 
suspension was centrifuged at 12, 000 rpm, 4 °C for 20 minutes. The supernatant was 
discarded and 0.5 M NaCl (aq.) was used to rinse the particles three times. The second 
layer was constructed by adding the particles to 30 ml of the chitosan solution for 20 
minutes. The centrifugation and rinse process was the same as that for building up of the 
first layer. The negatively charged type I collagen and positively charged chitosan were 
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alternatively used to treat the particles. The layer-by-layer building steps were repeated 
six times to construct three bilayers on the nanoparticles. Finally, the resulting core-shell 
nanoparticles were rinsed with 40 ml DI water for six times, and lyophilized as 
mentioned for core particles.	  
3.5 Size Distribution 
Four samples were prepared, including PGA core particles, PGA/(Col) cores with one 
layer of type I collagen, PGA/(Col/Chi) cores with one bilayer, and PGA/(Col/Chi)3 core-
shell particles with three bilayers. Each sample of the particles was prepared in aqueous 
solution at 0. 01 mg/ml. In order to avoid agglomeration that may significantly affect the 
result, each sample was ultrasonicated with 10 % intensity for two minutes and measured 
immediately.  
    The size distribution of each sample was measured by dynamic light scattering (DLS), 
which is a non-invasive, well-established technique. One typical application of DLS is to 
determine the size distribution of small particles in suspension or polymers in solution. 
The principle is based on the fact that all particles, polymers, and small molecules in 
suspension undergo Brownian motion.  If they are hit with a laser, the light will scatter in 
all directions, as long as the particles are smaller than the laser wavelength, and a time-
dependent fluctuation of the intensity of the scattered light can be observed. The intensity 
fluctuation is dependent on particle size, because the smaller particles move more rapidly.  
Analysis of intensity autocorrelation function provides the diffusion coefficient of the 
particles, and the hydrodynamic radius is related by Stokes-Einstein Equation. 
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3.6 Morphology 
The morphology of core particles and core particles with three bilayers was observed 
with SEM. Each sample was suspended in DI water, sonicated for 1-2 minutes, and 
immediately applied to a metal grid. The metal grid was air dried, and no gold sputtering 
was employed.  
3.7 Fourier Transform Infrared Spectroscopy (FTIR) 
As for other absorption spectroscopy (e.g. UV-Vis spectroscopy), the goal of FTIR is to 
measure how well a sample absorbs light at each wavelength. The difference is that this 
method uses a beam containing many different frequencies of light rather than a 
monochromatic beam. The test method also uses beams with different combinations of 
light frequencies to obtain interferogram due to wave interference. The test process is 
repeated for many times to gather raw data (light absorption) at each combination. To 
obtain the spectrum, a computer gathers and processes the data with a common algorithm 
called the Fourier transform. 
   FTIR analysis was performed on the samples of lidocaine and lidocaine-loaded PGA 
nanoparticles. Each sample was mixed with solid KBr to reach a concentration of 
approximately 10% by weight. The mixture was pressed to form a small round disk and 
examined from 4,000 to 600 cm-1. 
3.8 Zeta Potential 
Zeta potential is a measurement of the magnitude of the electrostatic charge repulsion or 
attraction between particles, and is one of the fundamental parameters to affect stability.  
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For charged particles in a suspension, an interfacial double-layer structure is usually 
formed on the surface, as shown in Fig. 8.  The first layer (stern layer) is compacted with 
ions of opposite sign from the surrounding solvents.  Due to thermal motions of solvent 
molecules and ions, this countercharge stretches out for some distance thereby forming a 
loose second layer called diffuse layer. Zeta potential is the potential difference between 
the dispersion medium and the stationary layer of fluid attached to the dispersed particle. 
A value of ±30 mV can be taken as the line that separates stable and unstable suspensions.  
Particles with zeta potential more positive than +30 mV or more negative than -30 mV 
are normally considered stable. 
    In aqueous media, the pH of the sample is one of the most important factors that affect 
its zeta potential. For the core particles, and all the nanoparticles with chitosan as the 
outmost layer, 10 mM KCl (aq., pH~3) was used to prepare the suspensions.  For 
nanoparticles with collagen as the outmost layer, 10 mM KCl (aq., pH~8) was employed. 
This was done in order to show the stability of the particles during the fabrication process. 
Since oppositely charged polyelectrolytes were used alternatively to construct layers, a 
charge reverse was expected as the layer growth. Furthermore, the PGA core particles 
and core-shell particles with three bilayers PGA/(Col/Chi)3 were also measured in PBS to 
show the stability in physiological conditions. 
    Samples were measured with Brookhaven ZetaPALS, which applies an electric field to 
a suspension and measures how fast a particle can move. This process is called 
electrophoresis. The larger the charge it carries, the faster the particle will move. 
	  35	  
 
Figure. 8 – Diagram showing a double-layer structure on a negative charged particle 
surface [79] 
 
3.9 Drug Loading  
The amount of lidocaine loaded into the particles was determined by a UV-vis 
spectroscopy method.  Since the particles contained several components, including 
lidocaine, PGA, type I collagen and chitosan, an appropriate wavelength was needed, at 
which lidocaine has the largest light absorption, while others do not. Aqueous solutions 
of lidocaine, type I collagen and chitosan were prepared separately at concentration of 0.1 
mg/ml and scanned at wavelength from 200 nm to 400 nm, respectively. PGA is 
insoluble in water, thus not considered. 
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    Standard solutions of aqueous lidocaine were prepared at several known concentrations 
and measured with UV-vis spectroscopy at the determined wavelength. A standard curve 
was set up by correlating the measured optical density subtracted by the blank control to 
the known concentration. The curve was used to determine drug loading and drug release 
by further interpolation. 
    Approximately 15 mg of each of PGA core particles, cores with one layer PGA/(Col), 
cores with one bilayer PGA/(Col/Chi), and core-shell particles PGA/(Col/Chi)3 with three 
bilayers was treated with excess 2 M NaOH (aq.) while heating. The treatment was done 
to degrade the polymers, and form sodium salts with the degraded oligomers, thereby 
completely release the model drug. After 20 minutes, the earlier opaque suspension was 
observed to become transparent. The resulting solution was extracted with 2 ml 
dichloromethane. Since lidocaine is hydrophobic and other compounds are salts that are 
soluble in water, lidocaine can be distributed primarily in dichloromethane and separated 
from other components. The organic phase would be used to determine the lidocaine 
content by interpolating with the standard curve. And the drug loading content was 
calculated by the following equation. 
!"#$  !"#$%&'  !"#$%#$   % = !"#$.!"#$%&"'(×!"#.!"#$%&'!"##!"#$%&'(                       (3-1) 
3.10 Drug Release Profile 
Approximately 25 mg of each of PGA core particles, cores with one layer PGA/(Col), 
cores with one bilayer PGA/(Col/Chi), and core-shell nanoparticles PGA/(Col/Chi)3 with 
three bilayers was suspended in 1 ml phosphate buffered saline (PBS) and incubated at 
37 °C. At specified time intervals, each sample was centrifuged, supernatant collected, 
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and 1 ml fresh PBS was used to resuspend the particles. The following sampling time 
point were used for the study: 2, 4, 6, 8, and 10 hours for the first day and then once a day 
for the next 19 days. The UV absorbance was measured for the supernatants with 
subtraction of the blank control of PBS. 
3.11 Statistical Methods 
In the present work, several statistical methods were employed to process original data. 
For average particle diameter and standard deviation, 
!!"# = !!!!!!                                                    (3-2) 
! = !! !! − !!"# !                                          (3-3) 
Where Davg – nm, the average diameter of nanopaticles,  
            Di – nm, an individual diameter of a group of nanoparticles,  
            Ni – dimensionless, the occurrence of each individual diameter,  
            N – dimensionless, the total occurrence,  
            and σ – nm, the standard deviation of the size distribution. 
    For drug loading contents, release samples and other samples with triplicates, similar 
statistical methods as Equation (3-1) and (3-2) were used. 
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CHAPTER IV 
 
 
RESULTS AND DISCUSSION 
 
4.1 Size Distribution 
The hydrodynamic diameters were measured with Brookhaven Zeta PALS, and size 
distributions were given for each sample. As shown in Fig. 9, the distribution range for 
each sample was quite narrow (± 2%). And the average diameters for the four samples 
were shown in Table. 2.  
 
Table. 2 – Average diameters for four nanoparticle samples. Data are means ± SD. 
Sample Average Diameter, nm 
PGA 157.6 ± 1.0 
PGA/(Col) 186.3 ± 1.7 
PGA/(Col/Chi) 221.9 ± 0.6 
PGA/(Col/Chi)3 391.2 ± 4.5 
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Figure. 9 – Hydrodynamic size distribution of a) – PGA core nanoparticles, b) – 
PGA/(Col), c) – PGA/(Col/Chi), and d) – PGA/(Col/Chi)3 
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    From these data, the thickness of each layer can be estimated. Two methods were used 
to estimate the thickness of each layer. One method is to subtract the two diameters and 
divided by 2 (accounts for symmetry) as follows. 
!ℎ!"#$%&&!"##$%!" = !!"#/(!"#)!!!"#!                                       (4-1) !ℎ!"#$%&&!!!"#$%& = !!"#/(!"#/!!!)!!!"#/(!"#)  !                                (4-2) 
    By using the above method, the thicknesses of the collagen and chitosan layers are 
approximately 14.4 ± 1.4 and 17.8 ± 1.2 nm, respectively. The thickness of the bilayer 
was determined by adding the thicknesses of one single layer of collagen and chitosan 
and was determined to be approximately 32.2 ± 2.6 nm.  
    The other method to calculate the thickness of the bilayer is to subtract the core 
diameter measurement from the diameter of the core with three bilayers measurement and 
divide by three (accounts for three bilayers) and by two (accounts for symmetry).  By 
using this method, the thickness of the bilayer was determined to be 39. 0 ± 0.9 nm.  
!ℎ!"#$%&&!"#$%&' = !!"#/(!"#/!!!)!!!"#!×!                                (4-3) 
    The two results vary by approximately 19% since the first method accounts for the 
thickness of the first bilayer, while the second method is based on an average thickness of 
the three bilayers. The difference indicates that the thicknesses for each bilayer is not 
uniform, Because the thickness of each layer is affected by many factors, including the 
surface charge of the particles, the concentration of polyelectrolytes, the concentration of 
NaCl, and the pH value of the solution. Although the latter three factors were maintained 
the same during the fabrication process, the surface charge was difficult to control.  
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4.2 Morphology 
    The morphology of core nanoparticles and core nanoparticles with three bilayers were 
obtained with an SEM. Fig. 10 shows that for both sample types, most of the particles are 
oval shape. Also, the SEM analysis was used to confirm the particle size. Fig. 10 Part (a) 
shows the morphology of core nanoparticles within some agglomerates. Some individual 
particles can be observed ranging from 100 to 200 nm as marked. The high intensity of 
the electron beam deforms the polymeric nanoparticles, resulting in large agglomerations, 
as shown at the bottom of the image.  In Fig. 10 Part (b), thousands of core nanoparticles 
with three bilayers form large agglomerate, which indicates a poor stability, compared to 
that of the core particles. The diameter of some randomly measured particles ranged from 
250 to 430 nm. Both images confirm the size distribution results with the previous results 
obtained by DLS.  
4.3 FTIR  
The successful entrapment of lidocaine within PGA was confirmed with FTIR spectra. 
Fig. 11 Part (a) shows the infrared spectrum of lidocaine with typical bands at 3283 cm-1 
(N-H stretching), 2823 – 2970 cm-1 (C-H stretching), 1683 cm-1 (C=O amide), 1496 and 
1594 cm-1 (aromatic C=C). When comparing the spectra in Fig. 10 Parts (a) and (b), there 
are obvious differences at 1215 cm-1 (C-O ester) and 1747 cm-1 (C=O ester), both of 
which indicate that lidocaine was incorporated with PGA. 
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Figure. 10 - SEM images of a) PGA core nanoparticles, b) PGA/(Col/Chi)3 
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Figure. 11 – FTIR spectra for a) lidocaine, and b) lidocaine loaded PGA nanoparticles. 
 
4.4    Zeta Potential 
Fig. 12 shows the zeta potential variations along the deposition of oppositely charged 
type I collagen and chitosan. The PGA core particles have a positive charge of 57.47 mV. 
After coated with the first layer of type I collagen, the positive potential of the particles 
was partially neutralized to 10.73 mV. The construction of the first layer did not result in 
a charge overcompensation, mainly because type I collagen is weakly charged of -7.13 
mV at pH ~ 8, at which the deposition was done. The subsequent adsorption of chitosan 
raised the charge to 49.53 mV. Although the expected charge reverse did not happen, the 
regular variation of charge after deposition of each new layer confirmed the layer growth. 
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The core nanoparticles, and the particles with one, two, and three bilayers have zeta 
potentials larger than 30 mV, which indicates good stability in an aqueous suspension. 
 
 
Figure. 12 – Charge variation ± s.d. of alternative deposition of type I collagen (Col) and 
chitosan (Col) on PGA nanoparticles.  Data are means ± SD; n=3. 
 
4.5 Drug Loading  
    Aqueous solutions of lidocaine, type I collagen and chitosan were scanned at 
wavelength from 200 to 400 nm, with deionized water as a control. As shown in Fig. 13, 
all three substances have significant absorbance at wavelengths below 210 nm. If the 
wavelength is larger than 280 nm, little UV light is absorbed by each sample. At 240 nm, 
lidocaine showed higher absorbance compared to the other two components. Therefore, a 
wavelength of 240 nm was used for further quantification of lidocaine. 
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Figure. 13 ? UV spectrum for 0.1 mg/ml aqueous solution of ? ? lidocaine, ? ? type I 
collagen, and ? ? chitosan. (Error bars were not shown because the readings were very 
stable; n = 3) 
 
    Since lidocaine is slightly soluble in water, standard solutions were prepared by 
dissolving lidocaine in deionized water to get concentrations of 0.01, 0.02, 0.03, 0.04, 
and 0.05 mg/ml. Each of these samples was examined at 240 nm with deionized water as 
control. The measured values minus the control value were plotted versus known 
concentrations. Fig. 14 shows a good linear correlation between the absorbance and 
concentration from 0.01 to 0.05 mg/ml. 
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Figure. 14 – Standard curve for lidocaine from concentration of 0.01 to 0.05 mg/ml. 
(Error bars were not shown because the readings were very stable; n = 3) 
 
    The drug loading content (average and standard deviation) for four samples was 
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into the aqueous solution during the coating process. The aqueous phases in the 
extraction processes were also tested. However, the concentration was too low to be 
detected. This result could be confirmed with the work of Wang et al. [80] that the 
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Table. 3 – Drug loading contents for four nanoparticle samples. Data are means ± SD; 
n=3. 
Sample Drug loading content, wt. %  
PGA 2.65 ± 0.23 
PGA/ Col 2.54 ± 0.15 
PGA/ (Col/Chi) 2.37 ± 0.18 
PGA/ (Col/Chi)3 1.82 ± 0.20 
 
4.6 In vitro Drug Release Profile  
The in vitro drug release for the four samples was recorded and compared as shown in 
Fig. 15. The data in Fig. 15 Part (a) shows that for all four samples there was sustained 
drug release over at least 20 days, with no significant burst release. Comparing the coated 
particles to the uncoated particles, the release pattern shows no significant difference, 
although the release rates are not the same. Within the first ten hours, all the coated 
particles released drug at a faster rate than the uncoated particles, as shown in Fig. 15 Part 
(b). One possible explanation is that a small amount of lidocaine, the model drug, may 
have diffused to the surface of the particle during the LbL coating process. The amount of 
drug at or near the surface would be released first when the particles are added to an 
aqueous solution. Since many drugs require a double dose consisting of an initial high 
dose followed by a lower, sustained dose, the relatively rapid drug release from the 
coated nanoparticles in the first few hours is desirable for reaching the therapeutic drug 
level in a short period. After the first ten hours, the rate of drug release decreases and is 
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sustained over the 20 day test period. This indicates a near linear drug release profile for 
the coated nanoparticles as a trivial effect of the coated layers. Also, the release rates for 
particles with different number of layers are close to each other. Although the core PGA 
nanoparticles were coated with polymers by LbL, they were not sealed tightly and there 
could exist nanoscale openings among polymer fibrils. For the small molecule model 
drug, the openings are large enough for the drug to pass through, and the shell does not 
act as a barrier to the drug release.  After 20 days, the release samples became 
nonuniform and supernatants obtained with centrifugation were not clear as those before. 
These changes indicate that the polymers in the core-shell nanoparticles degraded 
significantly, and lidocaine could not be separated from the polymer fragment by 
centrifugation. The broken nanoparticles could not be considered as controlled drug 
delivery device anymore, so the test was stopped.
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Figure. 15 ? Drug release test ? s.d. in PBS, 37.4 ?C for ? ? core nanoparticles PGA, 
* ?PGA/(Col), ? ?PGA/(Col/Chi), ? ? PGA/(Col/Chi)3. Error bars were not shown for 
Part (a), due to the small error associated with each measurement; n = 3.  For Part (b), 
data are means ± SD; n=3.  
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CHAPTER V 
 
 
CONCLUSIONS AND FUTURE OUTLOOK 
 
5.1    Conclusions 
The main objective of this research was to develop a novel ocular drug delivery system to 
provide sustained and controlled drug release over a long period of time. The system was 
designed as a core-shell structured nanoparticle with the model drug entrapped within the 
core. PGA was selected to fabricate the core, and type I collagen and chitosan were used 
alternatively to construct the shell with three bilayers by LbL method, which was the 
most important technology used during the fabrication process.  
This study demonstrated that PGA could be used to fabricate nanoparticles, and weak 
polyanion type I collagen and strong polycation chitosan could interact with each other 
through electrostatic force to form self-assembled bilayers. The resulting core-shell 
nanoparticles exhibited efficient drug loading content and controlled in vitro drug release 
profile sustained up to 20 days without any sudden burst.  
When comparing drug loading, the content for the core nanoparticles in this study at 
2.65 ± 0.23 wt. % is similar to other studies, such as reported by Braunecker et al. [55]
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with theophylline loaded in PGA matrix with 5 wt. % content.	  	  Drug loading content is 
limited by the particle size and decreases as the size decreases. When comparing drug 
release, the in vitro drug release of the present research showed a similar zero-order 
pattern comparable to other nanoparticle systems, such as estrodial (hydrophobic, Mw 
272.38) loaded PLGA nanoparticles (diameter ranging from 95.4 to 583 nm) by Sahana 
et al. [81]. 
In comparison with other existing nonsurgical approaches, this core-shell structured 
nanoparticle can be expected to deliver ophthalmic drugs for weeks with several benefits. 
Unlike some unstable systems, the core-shell nanoparticles are stable and can be stored in 
a dry and cool environment for months as we use the cool stored samples to repeat 
experiments and see no difference. The core-shell nanoparticles can be conveniently 
administered in an aqueous suspension, just like the eye drops. Since an aqueous solution 
with low viscosity will be employed as the dispersant, the administration will not cause 
blurred vision as ointments do. The mucoadhesive shell of the particles can still provide a 
long residence time on the ocular mucous membrane, and thereby improve the 
bioavailability. This treatment will not involve invasive procedures as the intended use. 
Drug release from the core-shell nanoparticles is controlled and sustained, which reduces 
the reverse side effects and the administration frequency.  
5.2    Future Outlook 
For future studies of this novel ocular drug delivery system, the mucoadhesive 
properties need to be investigated, because these properties determine the residence time 
for the particles, which significantly affects the bioavailability. Eventually, in vivo testing 
needs to be completed for the system. In vivo testing provides abundant information, 
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including the effect of in vivo conditions on the drug release profile, possible irritation, 
degradation kinetics, and the effect on normal vision. By measuring the amount of 
nanoparticles administered and the in vivo drug release rate, the amount of total drug 
delivered to the tissue can be estimated.  Furthermore, a mathematical model could be 
derived to describe the drug release from the PGA nanoparticles. Because this type of 
polymer degrades faster than many other polymers, such as poly(lactic-co-glycolic acid), 
the drug release will be significantly affected by both the concentration gradient as well 
as the polymer degradation rate, which is more complex than other systems. These 
additional studies will provide a better understanding of the drug release process in a 
quantitative manner. 
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Over the past years, topical ophthalmic drug administration has been limited due to low 
bioavailability. Conventional eye drops have approximate 95% loss, and the washout can 
result in significant side effects. Ointment was employed to prolong the residence time of 
the drug at the eye surface, but the application can result in irritation and blurry vision. 
Although some invasive methods (ex. intravitreal injection) were developed for direct 
delivery of the drug, these methods have various drawbacks, such as poor patient 
compliance and possibility of retina detachment by frequent applications. 
    To improve sustained delivery of drugs to the eye in a non-invasive way, we designed 
a novel core-shell nanoparticle that can be easily applied in a suspension. The core 
nanoparticles were fabricated by loading lidocaine as a model drug within polyglycolide 
nanoparticles. Then the core nanoparticles were coated alternatively with oppositely 
charged type I collagen and chitosan to obtain multilayers.  
    FTIR spectra and variation of zeta potential were employed to demonstrate successful 
drug loading in the core and layer growth of the shell, respectively. The resulting core-
shell nanoparticles were found to be oval in shape, 391.2 ± 4.5 nm in diameter, and 
loaded with 1.82 ± 0.20 wt. % of lidocaine (model drug). The in vitro drug release was 
measured for 20 days showing no sudden burst and close to a first order release profile. 
The shell showed slight modification of release rate at the beginning of the release test. 	  	  
 
 
